10 clinical trials to watch in the first half of 2026
BioPharma Dive••business
Key Points:
- Eli Lilly dominates the obesity drug market with its top-selling treatment Zepbound and is poised to launch a novel oral incretin weight-loss drug; upcoming Phase 3 trials (Triumph-1, -2, -3) for retatrutide, a triple-acting drug, could further solidify its lead by demonstrating superior weight-loss results.
- Merck acquired Cidara Therapeutics for over $9 billion to develop CD388, a long-acting antiviral for seasonal influenza, with a pivotal late-stage trial (ANCHOR) ongoing to evaluate its preventive efficacy over a full flu season.
- Regenxbio’s gene therapy RGX-202 for Duchenne muscular dystrophy is in Phase 3 trials, aiming to
:max_bytes(150000):strip_icc()/GettyImages-22400154171-19eb2573d96647f8894478942b5721be.jpg)
